Skip to main content
Search

Pharmacotherapy for obesity 2 - pharmacological agents in current use & under development

Part 2 of 2
Published on December 31, 2018 Archived on February 27, 2025   46 min

A selection of talks on Cardiovascular & Metabolic

Please wait while the transcript is being prepared...
0:00
Welcome back to the second part of this talk where I'll be reviewing the medications that are approved somewhere in the world for managing obesity or, are under active development at the moment.
0:18
So, what pharmacotherapy do we have? The drugs listed in the next slide, are those that have been approved for use in one or another country around the world and there are seven of them at the moment: phentermine, topiramate, a combination of phentermine and topiramate, orlistat, liraglutide, lorcaserin, and naltrexone plus bupropion. We should say when looking at this slide that all except orlistat work in the brain to suppress hunger.
0:60
The next slide is the first of the studies that we'll discuss that was published in 1968 where they investigated phentermine.
1:12
They studied 108 women, aged between 21 and 60 years who were obese, and they divided the group into three groups of 36 subjects each, that were all placed on a 1000 calorie diet, and then, group one was placed on placebo- they were given four weekly supplies. Group two was given phentermine 30 milligrams, and group three, was given phentermine for one month, alternating with placebo the next month and then, back again to phentermine.

Quiz available with full talk access. Request Free Trial or Login.

Show
Hide

Pharmacotherapy for obesity 2 - pharmacological agents in current use & under development

Embed in course/own notes